RxDoctor Payments Data

Jamie Greenert, APRN

Nurse Practitioner · Shepherdsville, KYNPI 1124571880

Payments from drug & device makers

$2,972in general payments, 2019–2025

Across 165 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$488
  • Lilly USA, LLC$393
  • Pfizer$254
  • GSK$228
  • Novo Nordisk$216
  • Axsome Therapeutics, Inc.$160
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$2,972100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,972 in reported general payments places this provider in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$32,714
Medicare patients
91
Services billed
518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$35,783
EliquisApixaban39$28,757
MounjaroTirzepatide22$28,521
OzempicSemaglutide22$17,910
VascepaIcosapent Ethyl13$9,986
FarxigaDapagliflozin Propanediol11$7,913
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$1,294
Albuterol Sulfate HfaAlbuterol Sulfate46$962
Atorvastatin Calcium153$881
Levothyroxine Sodium87$787
Omeprazole71$644
Metoprolol Succinate43$586
Metformin Hcl ErMetformin Hcl43$525
Rosuvastatin Calcium30$465
Pantoprazole Sodium47$430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$228$35,78357 claims
PfizerEliquis$254$28,75739 claims
Lilly USA, LLCMounjaro$393$28,52122 claims
Novo NordiskOzempic$216$17,91022 claims
AstraZenecaFarxiga$84$7,91311 claims
AbbVieSynthroid$488$39711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Shepherdsville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →